Thus, it is of great interest to develop small molecules and PROTACS that would either specifically target a discrete PRC1 complex or at least discriminate between cPRC1 and vPRC1 complexes, particularly in the context of cancers with high levels of H2AK119ub1, like BAP1 mutant tumors. This evidence concerns the gene BAP1 and cancer.